Harrow announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.
In commenting on the announcement, Mark L. Baum, chairman and CEO of Harrow, said, “Our mission has always been to help our eyecare professionals address their patients’ unmet needs and to make ophthalmic medications both accessible and affordable. The availability of these innovative compounded atropine formulations is in keeping with our mission. We believe ophthalmologists, optometrists, and the millions of Americans who may benefit from topical atropine therapy, will appreciate the tremendous value these patent-pending formulations offer.”
Key attributes of the ImprimisRx next-generation atropine formulations:
- Undergo validated analytical tests to ensure consistency, potency, and stability.
- Do not contain either preservatives or boric acid.
- Have a physiologic pH of 5.5.
- May be stored at room temperature for up to 180 days.
Eyecare professionals can order these new compounded atropine formulations for as low as $39 per 5mL bottle – either online at atropine.com or by calling or texting 615-437-4690 to speak to ImprimisRx Customer Service.
Compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products.